AtriCure Inc (ATRC) Stock
Key stats
- Market cap
- $2.93B
- Price / Earnings ratio
- 192.5x
- EPS (TTM)
- $0.30
- Volume
- Loading
- 52-week high
- $66.02
- 52-week low
- $25.36
Source: third-party data provider, as of November 13, 2026
Compare with ATRC
Recent news
What AtriCure (ATRC) Said on Its Q3 Earnings Call
What AtriCure (ATRC) Said on Its Q3 Earnings Call
ATRC
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
ATRC
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
ATRC
AtriCure Reports Third Quarter 2026 Financial Results
AtriCure Reports Third Quarter 2026 Financial Results
ATRCNews tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.69
- MACD 12/26/9
- 0.63
- EMA 9 of MACD
- 1.29
- MACD histogram
- -0.66
- SMA 50
- $57.32
- Price above SMA 50
- EMA 50
- $55.84
- Price above EMA 50
- SMA 200
- $38.90
- Price above SMA 200
- EMA 200
- $43.46
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $0.01 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
What AtriCure (ATRC) Said on Its Q3 Earnings Call
What AtriCure (ATRC) Said on Its Q3 Earnings Call
ATRCCompared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
ATRCAtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates
ATRCAtriCure Reports Third Quarter 2026 Financial Results
AtriCure Reports Third Quarter 2026 Financial Results
ATRC
AtriCure to Participate at Upcoming Investor Conferences
AtriCure to Participate at Upcoming Investor Conferences
ATRC
AtriCure to Announce Third Quarter 2026 Financial Results
AtriCure to Announce Third Quarter 2026 Financial Results
ATRC
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
ATRC
AtriCure CTO Sells 3,657 Shares
AtriCure CTO Sells 3,657 Shares
ATRC
Do Options Traders Know Something About AtriCure Stock We Don't?
Do Options Traders Know Something About AtriCure Stock We Don't?
ATRC
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?
ATRCNews tone: automated (AI) classification of the article's content, not a price prediction.
About AtriCure Inc
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Michael H. Carrel | CEO, President & Director | 1971 |
| Ms. Angela L. Wirick | Chief Financial Officer | 1978 |
| Mr. Douglas J. Seith | Chief Operating Officer | 1966 |
| Mr. Salvatore Privitera J.D. | Chief Technical Officer | 1967 |
| Mr. Justin J. Noznesky | Chief Marketing & Strategy Officer | 1978 |
| Dr. Vinayak Doraiswamy Ph.D. | Chief Scientific Officer | 1973 |
| Mr. Karl S. Dahlquist CCEP, J.D. | Chief Legal Officer | 1971 |
| Valerie Storch-Willhaus | Vice President of Corporate Marketing & Communications | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 47.69
- MACD 12/26/9
- 0.63
- EMA 9 of MACD
- 1.29
- MACD histogram
- -0.66
- SMA 50
- $57.32
- Price above SMA 50
- EMA 50
- $55.84
- Price above EMA 50
- SMA 200
- $38.90
- Price above SMA 200
- EMA 200
- $43.46
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $57.00
- Average
- $65.88
- High
- $70.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -15.5 | +6.1 | ||||||||||
| 2022 | -8.1 | +5.2 | -5.6 | -21.3 | -25.8 | +2.3 | +20.5 | -6.6 | -9.1 | +5.3 | +6.1 | -3.4 |
| 2023 | -3.5 | -12.8 | +6.8 | +5.7 | -0.3 | +7.8 | +13.1 | -19.7 | -4.2 | -19.9 | +1.3 | -2.4 |
| 2024 | -3.6 | +3.8 | -16.2 | -17.1 | -9.0 | +1.6 | +3.1 | |||||
| 2025 | +4.3 | |||||||||||
| 2026 | -0.1 | -15.1 | -7.8 | -0.7 | -4.7 | +5.7 | +27.0 | +24.9 | +14.9 | +14.3 | -3.9 |
